Search results for: “keytruda”
-
Media Room Article
Cancer Research Institute to Honor Leaders in Cancer Immunotherapy
CRI to honor Kenneth C. Frazier and Lauren Veronis with 2015 Oliver R. Grace Award for Distinguished…
-
Blog
ASCO 2015: Report from Day 4
More cancers prove treatable with checkpoint blockade therapy. Today: kidney, bladder, and ovarian cancer.
-
Blog
ASCO 2015: Report from Day 3
Immunotherapy for brain cancer and the results of a large clinical trial for patients with advanced melanoma.
-
Blog
ASCO 2015: Report from Day 2
The latest results from clinical trials of checkpoint inhibitors for lung cancer, liver cancer, and more.
-
Blog
ASCO 2015: What to Watch in Immunotherapy
Curious about what immunotherapy breakthroughs are coming at ASCO? Here’s a preview.
-
Blog
AACR 2015: Report from Day 2
Our report on the latest developments in cancer immunotherapy from day 2 at the annual AACR meeting…
-
Blog
Merck’s PD-1 Drug Outperforms Ipilimumab for Treatment of Advanced Melanoma
Data from a phase III trial indicate that Keytruda stands ready to become standard-of-care for advanced melanoma.
-
Blog
What Cancer Patients Need to Know About the Opdivo Approval
Now that Opdivo (nivolumab) has been FDA approved for two cancer types, many patients are wondering: what’s…
-
Blog
Big News: FDA Approves Opdivo (Nivolumab) for Lung Cancer
The PD-1 checkpoint inhibitor Opdivo® (nivolumab) is a new treatment option for patients with non-small cell lung…